secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dermata Therapeutics, Inc. (DRMA)
CIK:        0001853816
Form:       8-K
Filed at:   2024-06-07T23:59:59+00:00
Accession:  0001654954-24-007532
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dermata Therapeutics enters ATM equity facility for up to ~$1.16M
-----------------------------------------------------------------

- ATM Agreement with H.C. Wainwright for at-the-market issuance of common stock up to $1,157,761 aggregate market value.
- Commission rate 3.0% of gross sales price; expense reimbursement up to $70,000 plus periodic due diligence fees.
- Company has no obligation to sell; sales at prevailing market prices on Nasdaq under effective shelf registration statement.
- Offering terminates upon sale of all shares or earlier termination by either party.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1853816/000165495424007532/0001654954-24-007532-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1853816/000165495424007532/drma_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-24-007532

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer